Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591160 | 0.89 | HPGD (0.39) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| SCHEMBL18864371 | 0.81 | MAPT (0.38) | KDM4EALDH1A1LMNAHPGDTDP1 | |
| SCHEMBL14717102 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL2589296 | 0.80 | SMN1; SMN2 (0.43) | KDM4EALDH1A1LMNAHPGDTDP1 | |
| SCHEMBL14717869 | 0.78 | PRKAB2 (0.46) | KDM4EALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL18864295 | 0.78 | HTR6 (0.37) | KDM4EALDH1A1LMNAHPGDTDP1 | |
| SCHEMBL2595998 | 0.74 | EZH2 (0.37) | KDM4EALDH1A1MEN1KMT2APOLB | |
| SCHEMBL2594952 | 0.74 | EZH2 (0.52) | — | |
| SCHEMBL17970375 | 0.73 | EZH2 (0.37) | KDM4EALDH1A1KMT2A | |
| SCHEMBL14727054 | 0.73 | EZH2 (0.40) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | claimed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | claimed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | claimed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | claimed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | claimed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | claimed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885LMNA 3727/4885 |
| US-20130345200-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885LMNA 3727/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1253/4885ALDH1A1 45/4885LMNA 3700/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885LMNA 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.